Skip to main content
. 2020 Aug 31;18(3):423–433. doi: 10.9758/cpn.2020.18.3.423

Table 1.

Summary of RCTs of agomelatine for the treatment of generalized anxiety disorder

Study Drugs (mg/d) Patient (n) Mean age (yr) Duration (wk) Baseline MADRS Hamilton Anxiety Rating Scale Study location

Baseline Mean changea Responseb Remissionc
Stein et al. 2008 [17] PBO 58 41.7 12 11.7 ± 2.1 28.6 ± 3.8 −13.2 ± 9.5 27 (46.6) 13 (22.4) S. Africa, FN
AGO (25−50) 63 41.7 11.6 ± 2.9 29.0 ± 4.4 −16.6 ± 8.9 42 (66.7) 26 (41.3)
Stein et al. 2012 [18] PBO 113 47.0 26 NA 6.0 ± 2.6 3.6 ± 8.4 NA NA CN, DN, ET, FN, HG, and SW
AGO (25−50) 112 45.9 NA 5.9 ± 2.7 −1.6 ± 7.7 NA NA
Stein et al. 2014 [28] PBO 131 43.0 12 12.3 ± 2.4 28.2 ± 3.4 −10.6 ± 9.5 48 (36.6) 26 (19.9) FN, RU, PL, CZ, SL, AG, S. Korea
AGO (25−50) 139 43.6 12.0 ± 2.4 28.6 ± 4.0 −15.6 ± 9.4 89 (64.0) 51 (36.7)
Stein et al. 2017 [29] PBO 140 44.1 12 11.5 ± 2.6 28.8 ± 3.6 −6.9 ± 9.2 32 (22.9) 18 (12.9) FN, RU, PL, SL, Ukraine
AGO total 268 43.9 11.6 ± 2.4 28.8 ± 3.7 −15.91 ± 8.19 164 (61.2) 88 (32.9)
AGO (10) 130 43.6 11.8 ± 2.4 28.6 ± 3.5 −13.87 ± 8.7 67 (51.5) 33 (25.4)
AGO (25) 138 44.1 11.4 ± 2.4 29.0 ± 3.7 −18.7 ± 7.7 97 (70.3) 55 (39.9)

Values are presented as number (%) or mean ± standard deviation.

RCT, randomized, double-blind, placebo-controlled trials; MADRS, Montgomery and Åsberg Depression Rating Scale; SD, standard deviation; PBO, Placebo; AGO, Agomelatine; NA, not applicable; S. Africa, South Africa; FN, Finland; CN, Canada; DN, Denmark; ET, Estonia, HG, Hungary; SW, Sweden; RU, Russia; PL, Poland; CZ, Czech Republic; SL, Slovakia; AG, Argentina; S. Korea, South Korea; HAM-A, Hamilton Anxiety Rating Scale.

a

Primary efficacy measure; bResponse: 50% or more decrement of HAM-A from baseline to endpoint; c Remission: 7 or less in total HAM-A score at endpoint